Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 11, Issue 12, Pages 1695-1713Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.11.12.1695
Keywords
chromatin; histone acetyl transferases; histone deacetylase inhibitors; histone deacetylases; histones; suberoylanilide hydroxamic acid; trichostatin A
Categories
Ask authors/readers for more resources
Transformed cells, characterised by inappropriate cell proliferation, do not necessarily lose the capacity to undergo growth arrest under certain stimuli. DNA, genetic information, is packaged in chromatin proteins, for example, histones. The structure of chromatin may be altered by post-translational modifications (e.g., acetylation, phosphorylation, methylation and ubiquitylation) which play a role in regulating gene expression. Two groups of enzymes, histone deacetylases (HDACs) and acetyl transferases, determine the acetylation status of histones. This review focuses on compounds that inhibit HDAC activity. These agents have been shown to be active in vitro and in vivo in causing cancer cell growth arrest, differentiation and/or apoptosis. Several HDAC inhibitors are currently in clinical trials as anticancer agents and, in particular, hydroxamic acid-based HDAC inhibitors have shown activity against cancers at well-tolerated doses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available